Page last updated: 2024-12-07

propizepine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Propizepine is a tricyclic antidepressant (TCA) with anticholinergic and antihistaminic properties. It was synthesized in the 1960s and was initially marketed for the treatment of depression. However, its use was limited due to its side effects, including drowsiness, dry mouth, blurred vision, and constipation. Propizepine has also been investigated for its potential use in treating anxiety disorders, obsessive-compulsive disorder, and epilepsy. It is thought to exert its antidepressant effects by blocking the reuptake of serotonin and norepinephrine in the brain. Propizepine is currently not available in the United States but is still available in some European countries. Research on propizepine is limited, and further investigation is needed to fully understand its therapeutic potential and safety profile.'

propizepine: RN given refers to parent cpd; synonym UP 106 refers to HCl; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID112029
CHEMBL ID2104749
CHEBI ID135250
SCHEMBL ID49421
MeSH IDM0044250

Synonyms (27)

Synonym
propizepine
CHEBI:135250
6-[2-(dimethylamino)propyl]-11h-pyrido[3,2-c][1,5]benzodiazepin-5-one
09b57945v9 ,
propizepine [inn:dcf]
einecs 233-705-9
propizepinum
10321-12-7
unii-09b57945v9
up 106
propizepina
6,11-dihydro-6-(2-(dimethylamino)-2-methylethyl)-5h-pyrido(2,3-b)(1,5)benzodiazepin-5-one
propizepinum [inn-latin]
propizepina [inn-spanish]
vagran 50
CHEMBL2104749
5h-pyrido(2,3-b)(1,5)benzodiazepin-5-one, 6-(2-(dimethylamino)propyl)-6,11-dihydro-
propizepine [mi]
(+/-)-propiezepine
propiezepine, (+/-)-
propizepine [inn]
SCHEMBL49421
propizepin
YFLBETLXDPBWTD-UHFFFAOYSA-N
Q7250340
DTXSID20864247
6-[2-(dimethylamino)propyl]-6,11-dihydro-5h-pyrido[2,3-b][1,5]benzodiazepin-5-one
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organonitrogen heterocyclic compoundAny organonitrogen compound containing a cyclic component with nitrogen and at least one other element as ring member atoms.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (3)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.43

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.43 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.37 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.43)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (16.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]